Dr Andrew Östör joins Dr Marwan Bukhari to discuss their article, chosen as the June Editor's Choice article, which evaluates the 52-week efficacy and safety of risankizumab 150 mg in patients with active PsA who had previous inadequate response/intolerance to one or two biologic therapies (Bio-IR) or one or more conventional synthetic DMARDs (csDMARD-IR).Listen now to hear the findings and what this means for future clinical practice! You can read this article [https://doi.org/10.1093/rheumatology/keac605] in Rheumatology.Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram. Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.